Aptevo wins $1.5 million CARE Fund grant for APVO451 IND-enabling work

Aptevo Therapeutics secured a $1.5 million non-dilutive grant from the CARE Fund to support IND-enabling work for its solid-tumor candidate APVO451. The funding aims to target development-candidate selection by the end of 2026, with IND-enabling studies planned for the first quarter of 2027.

Aptevo secured a USD 1.5 million non-dilutive CARE Fund grant to support IND-enabling work for solid-tumor candidate APVO451. * Funding targets development-candidate selection by year-end 2026; IND-enabling studies planned for 1Q27. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350537), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here